Project Orbis: Annual UK Approvals Down Since 2022, But MHRA Touts Advantages

 
• By Eliza Slawther
  
The MHRA says Project Orbis offers a faster route to market for cancer drugs in the UK • Source: Shutterstock

More from Review Pathways

More from United Kingdom